Janus Henderson Group PLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 144.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,552,392 shares of the biopharmaceutical company's stock after buying an additional 1,507,135 shares during the period. Janus Henderson Group PLC owned 3.35% of Xenon Pharmaceuticals worth $100,506,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Harbor Capital Advisors Inc. boosted its stake in Xenon Pharmaceuticals by 647.8% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 24,116 shares of the biopharmaceutical company's stock worth $940,000 after purchasing an additional 20,891 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in Xenon Pharmaceuticals by 7.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company's stock worth $27,843,000 after purchasing an additional 46,964 shares in the last quarter. Vestal Point Capital LP boosted its stake in Xenon Pharmaceuticals by 57.1% in the 3rd quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company's stock worth $32,480,000 after purchasing an additional 300,000 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock worth $172,315,000 after purchasing an additional 97,732 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in Xenon Pharmaceuticals during the 2nd quarter worth approximately $1,574,000. 95.45% of the stock is currently owned by institutional investors.
Xenon Pharmaceuticals Trading Down 2.2 %
XENE traded down $0.93 on Thursday, hitting $41.41. The company had a trading volume of 461,955 shares, compared to its average volume of 388,509. The firm has a market cap of $3.16 billion, a P/E ratio of -14.68 and a beta of 1.19. Xenon Pharmaceuticals Inc. has a 1 year low of $35.53 and a 1 year high of $50.99. The company's fifty day moving average price is $41.73 and its 200 day moving average price is $40.30.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01. During the same quarter in the previous year, the business earned ($0.73) EPS. On average, analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Insider Activity at Xenon Pharmaceuticals
In related news, Director Gary Patou sold 4,891 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the sale, the director now directly owns 23,573 shares of the company's stock, valued at $968,378.84. This trade represents a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.52% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
XENE has been the subject of a number of recent research reports. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Raymond James reaffirmed an "outperform" rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Needham & Company LLC reissued a "buy" rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $57.45.
Read Our Latest Report on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
